Claims for Patent: 10,000,570

✉ Email this page to a colleague

Summary for Patent: 10,000,570

Title:	Antibody variants having modifications in the constant region
Abstract:	The present invention relates to positions in the constant region of antibodies, in particular the CH3 region of IgG4, which affect the strength of CH3-CH3 interactions. Mutations that either stabilize or destabilize this interaction are disclosed.
Inventor(s):	Aran Frank Labrijn, Stefan Loverix, Paul Parren, Jan van de Winkel, Janine Schuurman, Ignace Lasters
Assignee:	Genmab AS
Application Number:	US14/739,768

Details for Patent 10,000,570

Glossary

Subscribe to access the full database, or Get Started Free
Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Genentech, Inc.	ACTEMRA	tocilizumab	Injection	125276	January 08, 2010	⤷ Get Started Free	2035-06-15
>Applicant	>Tradename	>Biologic Ingredient	>Dosage Form	>BLA	>Approval Date	>Patent No.	>Expiredate

International Patent Family for US Patent 10,000,570

Subscribe to access the full database, or Get Started Free
Country	Patent Number	Estimated Expiration
World Intellectual Property Organization (WIPO)	2010063785	⤷ Get Started Free
United States of America	9085625	⤷ Get Started Free
United States of America	2021155699	⤷ Get Started Free
United States of America	2018319888	⤷ Get Started Free
United States of America	2015376282	⤷ Get Started Free
>Country	>Patent Number	>Estimated Expiration

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.